We took advantage of CRISPR/Cas9 genome editing to generate cells with levels of expression for APOL1 G1 and G2, comparable to those for G0, as well as APOL1 knock-out RCC. The gene discussed is APOL1; the disease is renal cell adenocarcinoma.